公开(公告)号：US20210253534A1

公开(公告)日：2021-08-19

申请号：US17236596

申请日：2021-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20170275256A1

公开(公告)日：2017-09-28

申请号：US15598734

申请日：2017-05-18

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY

IPC: C07D231/54 ,  A61K31/4745 ,  C07D471/06 ,  A61K31/4162 ,  A61K31/416 ,  C07D491/052 ,  C07D471/04 ,  A61K31/4439

CPC classification number: C07D231/54 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/04 ,  C07D471/06 ,  C07D491/052

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20200247757A1

公开(公告)日：2020-08-06

申请号：US16854762

申请日：2020-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20180298018A1

公开(公告)日：2018-10-18

申请号：US15569498

申请日：2016-04-29

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Xiaodong LIU ,  Valentina MOLTENI ,  John NELSON ,  Jason ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY

IPC: C07D491/052 ,  A61K31/4162 ,  A61K31/5377 ,  A61K31/635 ,  A61K31/427

CPC classification number: C07D491/052 ,  A61K31/4162 ,  A61K31/427 ,  A61K31/5377 ,  A61K31/635 ,  C07D493/04

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).